Table 1.

Literature review summary.

Reference number	Year of publication	Comments	Type of stimulation	Number of patients	Number of patients with long-term pain relief
[2]	2017		stSCS	46	32
[14]	2002		SCS	28	23
[15]	2012		stSCS	33	21
[16]	2011		SCS	11	4
[17]	2019	DRG focus trial	DRGS	4	3
[18]	2019		DRGS	3	0
[19]	2029		DRGS	2	1
[20]	2021		hfSCS	1	1
[21]	2018		hfSCS	1	1
[22]	2021		burstSCS	1	1
[23]	2021		DRGS	3	3
[13]	2021		SCS + DRGS	1	1
% Of patients with long-term pain relief	Affected dermatomes	Average pain reduction (%)	Follow-up, mo	Medication usage after stimulation
69.6	T5-L5	50.7	6–12	Reduction or discontinuation in 11 patients
82.1	C3-S1	89	29 average	Discontinuation in 13 patients
63.6	Cervical and thoracic	49	6	No patient required changes in drug doses
36.3	C5-L2	N/A	34.5	N/A
75	N/A	82.5	N/A	N/A
0	T1-L2	16,00	8	No changes
50	C8-T7	37.5	12	N/A
100	T2	90	7 days	N/A
100	C4-T1	78	N/A	Reduction of oxycodone usage
100	T2	62.5	6	Reduction in opioid dose
100	T5-T10	60	18	Reduction or discontinuation in all patients
100	C6-T1	60	2	Discontinuation of fentanyl usage